Potential risk of birth defects after acitretin discontinuation.
Maradit
H
H
Drug Safety, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Geiger
J M
JM
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D017255:Acitretin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000009:adverse effects*; D011247:Pregnancy; D011256:Pregnancy Outcome; D012307:Risk Factors
D007641:Keratolytic Agents; D017255:Acitretin